Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

Home/Biomarker

EGFR exon 19 deletion

Gene: EGFR · Type: mutation

Indications: Non-small cell lung cancer

Sensitivity Resistance CIViC Context

Linked CIViC Profile: EGFR EXON 19 DELETION

Evidence Level Distribution

Level A: 2Level B: 12Level C: 1Level D: 3

Level	Type	Direction	Significance	Disease	Drugs	Rating
A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	5
A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	5
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	4
B	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Anti-PD1 Monoclonal Antibody	4
B	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Anti-PD-L1 Monoclonal Antibody	4
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Dacomitinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	3
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	2
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	2
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	0